Market revenue in 2023 | USD 851.8 million |
Market revenue in 2030 | USD 1,317.4 million |
Growth rate | 6.4% (CAGR from 2023 to 2030) |
Largest segment | Pcr-based diagnostics |
Fastest growing segment | NGS DNA Diagnosis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | PCR-based Diagnostics, NGS DNA Diagnosis, In-Situ Hybridization Diagnostics, Microarrays-based Diagnostics |
Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Beckman Coulter, Bio-Rad Laboratories Inc, Thermo Fisher Scientific Inc, Illumina Inc, Danaher Corp, Hologic Inc, Siemens Healthineers AG ADR, Roche, Qiagen NV, Agilent Technologies Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to dna diagnostics market will help companies and investors design strategic landscapes.
Pcr-based diagnostics was the largest segment with a revenue share of 49.68% in 2023. Horizon Databook has segmented the China dna diagnostics market based on pcr-based diagnostics, ngs dna diagnosis, in-situ hybridization diagnostics, microarrays-based diagnostics covering the revenue growth of each sub-segment from 2018 to 2030.
In China, there has been a significant shift in death rates over the past 40 years from infectious diseases to NCDs. DNA testing can identify pathogens with high precision, enabling rapid and accurate diagnosis of infections like bacterial, viral, & fungal diseases.
This helps in tailoring the right treatment quickly. The main causes of this change have been risk factors like nutrition, physical inactivity, and smoking. Due to socioeconomic progress and demographic changes, China has experienced significant shifts in its mortality patterns over the past 40 years, moving from infectious diseases to NCDs.
This shift has been fueled by the widespread nature of risk factors, such as alcohol misuse, smoking, poor food, and physical inactivity; as a result, the leading causes of mortality in this country are now diabetes, cancer, Cardiovascular Disease (CVD), and Chronic Respiratory Diseases (CRD).
Horizon Databook provides a detailed overview of country-level data and insights on the China dna diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into China dna diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account